Neftaly: Addressing Barriers to Technology Transfer for Biomarkers

Biomarker technologies hold immense promise for transforming disease detection, treatment, and public health surveillance. However, the successful transfer of these innovations from laboratories to real-world settings—especially in low- and middle-income countries—faces a range of complex barriers. At Neftaly, we are committed to identifying and overcoming these challenges to ensure equitable access to biomarker-driven health solutions worldwide.

---

Understanding the Barriers

Effective technology transfer involves more than delivering tools; it requires enabling environments, strong systems, and collaborative frameworks. The key barriers to biomarker technology transfer include:

1. Limited Infrastructure

• Inadequate laboratory facilities and testing equipment
• Unreliable power, water supply, and internet connectivity
• Weak logistics for supply chain and cold storage

2. Human Resource Gaps

• Shortage of trained personnel for biomarker testing and interpretation
• Limited local expertise in new diagnostic platforms and quality assurance
• Brain drain of skilled professionals from low-resource settings

3. High Costs and Unclear Financing

• High upfront costs for devices and consumables
• Limited government and donor funding for diagnostic programs
• Lack of sustainable financing models for maintenance and scaling

4. Regulatory and Policy Challenges

• Lengthy and inconsistent regulatory approval processes
• Lack of national guidelines or standards for biomarker use
• Fragmented procurement and implementation pathways

5. Intellectual Property and Licensing Restrictions

• Restrictive IP agreements that limit access or local manufacturing
• High costs due to lack of licensing flexibility
• Barriers to adaptation or customization of technology

6. Data Governance and Ethical Concerns

• Lack of frameworks for ethical data collection, use, and sharing
• Concerns over patient privacy and sample ownership
• Community mistrust of foreign-developed technologies

---

Neftaly’s Strategies to Overcome Barriers

1. Strengthening Local Systems

• Upgrade laboratory infrastructure to support biomarker testing
• Provide essential equipment and maintenance support
• Enhance digital connectivity for test data collection and sharing

2. Investing in Capacity Building

• Train healthcare workers, lab technicians, and data analysts
• Support continuous education through local institutions
• Build leadership capacity for local health innovation

3. Enabling Cost-Effective Access

• Advocate for tiered pricing and pooled procurement models
• Support local manufacturing or assembly to reduce costs
• Design scalable and modular solutions tailored to resource availability

4. Supporting Regulatory and Policy Development

• Work with governments to streamline regulatory approvals
• Assist in drafting national biomarker implementation strategies
• Align transferred technologies with existing health policies

5. Facilitating Fair and Flexible Licensing

• Promote open-access or non-exclusive licensing agreements
• Engage technology originators in equitable transfer negotiations
• Support localization and adaptation of intellectual property

6. Promoting Ethical Use and Community Trust

• Develop transparent data governance frameworks
• Conduct community engagement to build understanding and acceptance
• Ensure informed consent and cultural sensitivity in implementation

---

Conclusion

Technology transfer for biomarkers is a powerful driver of global health equity—but only if the barriers to access, implementation, and sustainability are addressed head-on. At Neftaly, we take a system-wide, partner-driven approach to overcoming these obstacles, ensuring that biomarker innovations are not just shared—but successfully adopted, owned, and sustained by the communities that need them most.